Αποτελέσματα Αναζήτησης
2 Ιουν 2024 · Osimertinib is a recommended treatment for advanced non–small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant treatment for resected EGFR ...
form the field of thoracic oncology and provide new hope for patients with lung cancer. Here we provide a synopsis of the mechanisms of action and an up-date on the development of ADCs toward a new treatment paradigm for lung cancers. Molecular Mechanism of Action ADCs first arrived in the oncology clinic over two
ten percent of people with lung cancer have EGFR mutations present in their tumors. EGFR inhibitors—targeted therapies given in pill form—are often used to treat this type of lung cancer. Today, five medications are approved treatment options in the United States for lung cancer that has this gene mutation: • Erlotinib (Tarceva).
Advancements for treatment of early-stage NSCLC. The treatment landscape of resectable early-stage NSCLC is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as well as adjuvant targeted therapy.
13 Σεπ 2022 · FDA Immunotherapy Approval Marks a First for Lung Cancer. Atezolizumab is approved to treat some people with non-small cell lung cancer after surgery.
There are several types of treatment for lung cancer. You and your health care team will determine which choice is best for you after reviewing the type of lung cancer, the stage of your disease, your symptoms, and other health problems you may have. Lung cancer treatments are continuing to improve as new discoveries are made so it
21 Σεπ 2021 · THE FOOD AND DRUG ADMINISTRATION has approved Lumakras (sotorasib) for treatment of adult patients with non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy, and whose tumors bear a genetic mutation known as KRAS G12C.
